Vall d’Hebron Institute of Research (VHIR) is a multidisciplinary biomedical research center, with the aim to undertake high quality and competitive research at international level on the most prevalent diseases and the development of new methods of diagnosis and treatment. The Neurovascular Research Laboratory at VHIR is one of the leading stroke translational research groups in Europe.
Our clinical and laboratory work focuses on the identification of biomarkers to be used as diagnostic and prognostic tools in ischaemic and haemorrhagic stroke. By the use of plasmatic biomarkers we have identified relevant components of the cerebral ischaemic cascade.
We described for the first time in human stroke the involvement of matrix metalloproteinase (MMP)-10, MMP-13, thrombin-activable fibrinolysis inhibitor (TAFI) and other related molecules. Recently, “omics” techniques have allowed us to describe for the first time the “brain and microdialysis proteomes of human stroke” giving us extensive experience in the discovery of new promising candidate biomarkers in the field of neurovascular diseases.
This group leads WP-3 on Biomarkers and will provide data and expertise concerning stroke biomarkers to be used adding complementary information to improve the predictability of recurrent ischaemic and haemorrhagic events in patients with Intracerebral Haemorrhage (ICH) and Atrial Fibrillation (AF) in order to better personalize the decision if they are good candidates for long-term anticoagulant therapy incorporating the tested biomarkers into a new comprehensive multidisciplinary prediction tool for stroke and ICH recurrence in ICH patients in need for long-term anticoagulation to personalize decision making in secondary stroke prevention.
In fact, the Neurovascular Research Lab at VHIR will be the reference for the PRESTIGE-AF Bio-Bank and for testing and evaluation of stroke blood biomarkers from the consortium.
View All Partners